Technology

DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer’s Disease

Published

2 years ago

July 8, 2024

BEIJING, July 8, 2024 /PRNewswire/ — DP Technology, an “AI for Science” paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer’s disease (AD).

AD is the most frequent cause of dementia (60%~70%), affecting approximately 57 million people worldwide. Neurovascular dysfunction is an early and predominant event in AD development, independent of classic amyloid pathology. Lp-PLA2 is a phospholipase secreted primarily by inflammatory cells, including peripheral macrophages and CNS microglia. It hydrolyzes oxidized phospholipids typically on low-density lipoprotein (LDL), producing lysophosphatidylcholine (lysoPC) and other potent proinflammatory factors. LysoPC is a key inflammatory mediator on vascular endothelial cells, causing vascular pathology including vessel leakage and BBB damage. The inhibition of Lp-PLA2 by Rilapladib significantly slowed down AD progression and repaired BBB damage in a Phase IIa trial.

DPT0416 is a novel CNS-penetrable Lp-PLA2 inhibitor, exhibiting higher potency, better ADME and physicochemical properties than Rilapladib. In animal models, DPT0416 showed improvement in BBB integrity and a reduction in brain inflammation. The IND-enabling studies are ongoing.

“Alzheimer’s disease imposes increasing burdens on the world. Approvals of three anti-amyloid β (Aβ) antibodies mark a pivotal moment in the fight against AD, but the modest clinical efficacy and side effects highlight the complexity of AD and call for more novel interventions with better efficacy. The future treatment of AD should address multiple aspects of the disease, including anti-oxidants, anti-inflammation, and enhancing brain resilience, among others,” said Xiaomin Zhang, Head of Drug Discovery at DP Technology. “Targeting Lp-PLA2 is a novel therapy that addresses multiple factors beyond amyloid. Given rilapladib’s positive clinical results, the better molecule DPT0416 is expected to bring more benefits to AD and dementia patients.”

“DP Technology is revolutionizing the AI for Science landscape by integrating ‘AI + Simulation + Experiments’ into our processes to address significant medical needs,” said Weijie Sun, Founder and CEO of DP Technology. “The successful identification of DPT0416 highlights the power of our RiDYMO® platform, particularly the contributions of the Uni-FEP and Uni-QSAR modules in enhancing molecular interactions, drug-like characteristics, and BBB penetration. These real-world applications of our cutting-edge algorithms signify an important progression towards our envisioned future. We look forward to forging partnerships with trusted collaborators to advance this initiative to the next pivotal stage.”

The RiDYMO® drug design platform integrates various AI and physical algorithms, dedicated to the development of drugs for “undruggable” targets and “best-in-class” molecules. As one of its core algorithms, Reinforced Dynamics (RiD) has a significant advantage in the sampling efficiency of molecular dynamics simulation. By fully leveraging the high-dimensional representation capabilities of neural networks, RiD can efficiently capture dynamic conformational changes in complicated biomolecular systems.

The RiDYMO® platform is dedicated to studying the dynamics of biological systems and revealing cryptic binding sites, encompassing a range of challenging systems including protein-protein interactions (PPIs), intrinsically disordered proteins (IDPs), membrane proteins, RNA, and others. Its effectiveness has been confirmed through validation on challenging targets, including the c-Myc protein, c-Myc RNA, GPX4 protein, Kv1.3 protein, and others.

About DP Technology

DP Technology, an “AI for Science” new paradigm-driven company, dedicated to applying Artificial Intelligence and Molecular Simulation algorithms to solve important scientific problems by combining advanced computational methods.

Relying on DP Technology’s Dynamics-based drug design platform, RiDYMO®, we have set up a world-leading hit discovery platform. The team has established external collaborations and built up strong internal pipeline, focusing on three areas of CNS, oncology and autoimmune diseases.

For collaboration and further information，please contact Dr. Xiaomin Zhang (zhangxm@dp.tech).

References:
[1] Alzheimers. Dement. 17(Suppl 10), e051496 (2021).
[2] Nat. Med. 25, 270-276 (2019).
[3] Med. Res. Rev. 40, 79-134 (2020).
[4] Alzheimers. Dement. 1, 131-140 (2015).
[5] Diab. Vasc. Dis. Res. 14, 200-213 (2017).

View original content to download multimedia:https://www.prnewswire.com/news-releases/dp-technology-announces-nomination-of-development-candidate-a-cns-penetrable-lp-pla2-inhibitor-for-alzheimers-disease-302190631.html

SOURCE DP Technology

Technology

Infineon wins patent infringement case against Innoscience

Published

57 minutes ago

June 18, 2026

MUNICH, June 18, 2026 /PRNewswire/ — The District Court Munich, Germany (Landgericht München I) today ruled in favor of Infineon Technologies in two further of the patent infringement cases – specifically one based on a patent one based on a utility model – concerning gallium nitride (GaN) technology between Infineon and Innoscience.

The cases concern the unauthorized use of GaN technologies patented by Infineon by the Chinese company Innoscience. With today’s rulings, the court prohibits Innoscience from manufacturing, selling, and marketing additional patent-infringing products in Germany. Furthermore, the court has ordered Innoscience to pay damages to Infineon.

This marks Innoscience’s third and fourth legal defeat in a series of court cases, each of which found that Innoscience’s products infringe Infineon’s patents. Courts and authorities in both Germany and the United States have repeatedly concluded that Innoscience’s products infringe Infineon’s intellectual property rights. Prior rulings include the decision against Innoscience from August 1, 2025, in an initial German proceeding. Furthermore, on May 7, the Full Commission of the U.S. International Trade Commission (ITC) found that Innoscience had infringed an Infineon patent in the field of gallium nitride (GaN) technology. Additional proceedings regarding the infringement of other Infineon patents are pending in the U.S. and Germany.

GaN plays a pivotal role in enabling high-performance and energy-efficient power systems in a broad range of applications, including renewable energy systems, data centers, industrial automation, and electric vehicles (EVs).

“Today’s ruling demonstrates the value of our GaN portfolio and underscores our commitment to vigorously defending our intellectual property and promoting fair competition,” said Johannes Schoiswohl, Senior Vice President and Head of Infineon’s GaN Systems Business Line.

Infineon continuously strengthens its position as a leading integrated device manufacturer (IDM) in the GaN market with the industry’s broadest IP portfolio, comprising approximately 450 GaN patent families. The company remains dedicated to fostering innovation and advancing semiconductor technology to address the world’s most pressing challenges, from decarbonization to digital transformation.

About Infineon
Infineon Technologies AG is a global semiconductor leader in power systems and IoT. Infineon drives decarbonization and digitalization with its products and solutions. The Company had around 57,000 employees worldwide (end of September 2025) and generated revenue of about €14.7 billion in the 2025 fiscal year (ending 30 September). Infineon is listed on the Frankfurt Stock Exchange (ticker symbol: IFX) and in the USA on the OTCQX International over-the-counter market (ticker symbol: IFNNY).

Further information is available at www.infineon.com
This press release is available online at www.infineon.com/press
Follow us: Facebook – LinkedIn

Contact:
Andre Tauber,
andre .tauber@infineon.com,
Tel. +49 89 343 6705

View original content:https://www.prnewswire.co.uk/news-releases/infineon-wins-patent-infringement-case-against-innoscience-302804725.html

Technology

The Inner Circle acknowledges Alan R. Mann as a Pinnacle Professional Member Inner Circle of Excellence

Published

57 minutes ago

June 18, 2026

MOORESVILLE, N.C., June 18, 2026 /PRNewswire/ — Prominently featured in The Inner Circle, Alan R. Mann is recognized as a Pinnacle Professional Member Inner Circle of Excellence for his contributions to Data Analytics and Decision Support.

Alan R. Mann has built a distinguished career in data analytics defined by precision, innovation, and a steadfast commitment to data integrity. With 36 years of experience spanning government, private sector, and health care environments, he is widely respected for transforming complex data into actionable insight that supports informed decision making and improved outcomes.

Since 2023, Mr. Mann has served as a data analyst and senior decision support analyst at Highmark Health, where he manages reporting package responsibilities for the Encompass team. In this role, he develops advanced programming that enables sales teams to deliver data driven client presentations, compare client profiles across multiple health care benefit metrics, and measure outcomes for up to nine chronic conditions.

Mr. Mann’s responsibilities also include evaluating additional coverage measurements and product performance metrics, conducting data discovery to integrate internal database sources, and reducing manual transcription through streamlined data workflows. He finalizes data integration efforts that improve reporting efficiency and supports enhancements to pharmacy focused reporting products, ensuring accuracy and consistency across all deliverables.

A critical component of his work involves designing comprehensive test plans to validate the accuracy and reliability of program outputs. When discrepancies or uncertainties arise, Mr. Mann rigorously retests and validates results, reinforcing his commitment to quality, precision, and trustworthy analytics. His expertise across government, health care, data science, and business analytics continues to add measurable value to the organizations he supports.

Mr. Mann earned a Bachelor of Arts degree from the University of Delaware and a Master of Science degree from Capella University. He further expanded his technical skill set through certification in artificial intelligence from the Texas McCombs School of Business. His professional affiliations include SAS, SASUG, Scouting America, and AEPhi, reflecting both his technical engagement and community involvement.

Outside of his professional work, Mr. Mann enjoys traveling, collecting model and toy trains, and playing guitar. He credits much of his success to the guidance of his mentor, Barry Morstan, and expresses deep gratitude to his wife, Louis, and his parents, Gilbert and Muriel, for their continued love and support.

Looking ahead, Mr. Mann plans to continue contributing to his organization while gradually preparing for the next phase of his professional journey, confident in the lasting impact of his work in data analytics and decision support.

Contact: Katherine Green, 516-825-5634, editorialteam@continentalwhoswho.com

View original content:https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-alan-r-mann-as-a-pinnacle-professional-member-inner-circle-of-excellence-302804593.html

SOURCE The Inner Circle

Technology

Aquarius.io Launches Press AI & PR Spotlight: Your New AI Team

Published

57 minutes ago

June 18, 2026

They Call it “The Unfair Advantage”.

LOS ANGELES, Jun 18, 2026 /PRNewswire/ —

Talent is not enough without a team.

Most people do not lose because they lack talent. They lose because they do not have a team behind them. Aquarius is out to change that. Two new tools, Press AI and PR Spotlight, put a full news team and a full marketing department in one person’s hands. It is the kind of firepower everyone needs go scale. See it all at Aquarius.io.

Press AI: a full news team for one person

Press AI is a full news team for one person. Give it a story and it researches live sources, checks the facts, turns your interviews into clean, quotable transcripts, and hands back a finished piece with sources attached, ready to file. It does the work of an entire team, so one reporter can chase more leads, break more stories, and beat every deadline.

“Talent is everywhere. The team behind it is not,” said Chaela Harrell, a co-founder of Aquarius. “Aquarius gives one person the power of a whole company. We are your unfair advantage.”

PR Spotlight: your own marketing department

PR Spotlight is a full marketing department in a single tool. Answer a few questions and it researches your brand, then builds investor grade pitch decks and complete media kits, designs your logo, and even handles your contracts, letting you upload, send, sign, and receive them through DocuSign. Together, Press AI and PR Spotlight do the work of an entire team, putting serious media and marketing power in anyone’s hands. Press AI and PR Spotlight are available now at Aquarius.io. Take a look, test it and see what the hype is about.

The rest of the Aquarius family

Press AI and PR Spotlight join a whole family of Aquarius tools: Muse Lab for image and video, Chronicles for cinematic storytelling, Viral AI for social content, and Aria, a voice driven executive assistant. The platform is self serve, so you only pay for what you make. Every tool is built on one idea: give one person the team they never had. That is your unfair advantage.

Press AI and PR Spotlight are the next step in what Aquarius set out to do: put professional grade tools in the hands of the people who were never handed a team.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aquariusio-launches-press-ai–pr-spotlight-your-new-ai-team-302804726.html

SOURCE Aquarius.io